-
ASEAN calls for open straits as US-Iran war casts shadow
-
MEXC's "Kickoff Fest" Trading Event Concludes with Top Individual Reward of 27,352 USDT
-
Ford and Geely to form joint venture at struggling Spain plant
-
Oil soars close to $100 on fresh Mideast attacks
-
Russia warns US against Ukraine arms sales in Manila meeting
-
India's angry Gen Z protesters say Modi must fix accountability
-
New UK PM announces tax cut for struggling pubs
-
Barca sign Adeyemi from Borussia Dortmund
-
Supporters flood India's 'cockroach' protesters with food
-
EasyJet profits nosedive on Mideast war
-
Modi vows punishment for exam leaks fuelling India protests
-
EU fines Google 890 mn euros, risking US fury
-
Norway set to make formal complaint to FIFA over Balogun red card saga
-
France evacuates thousands of tourists as fire rages in pine forest
-
Floods in northeast India kill at least 41
-
French Jewish DJ sues after activists disrupt stage show: lawyer
-
Nestle siphons off bottled water business into joint venture
-
Nokia says AI, cloud boosted sales in second quarter
-
Hundreds hospitalised in Japan heatwave 'disaster'
-
Repsol says profit more than triples on higher oil prices
-
Renault says sales stalled in first half
-
TotalEnergies says profit doubled on Mideast war
-
EasyJet says profits nosedive on Mideast war
-
Giant swing on Swiss peak aims to boost summer tourism as Alps warm
-
Modi vows punishment for exam fraud fuelling India protests
-
ASEAN to call for open straits as US-Iran war casts shadow
-
Six candidates in race to lead UN set for televised debate
-
AI catches up with humans to score 100% at top maths contest
-
Comic-Con kicks off with Marvel's return
-
South Korea election office raided in fake turnout figures probe: investigators
-
Dutch riders dreaming of crazy party corner of Alpe d'Huez
-
Killer whales: orcas blow fish to bits 'for fun', study finds
-
Houthis target Red Sea shipping as US hits Iran
-
Deadly wildfires force thousands from homes in parts of Europe
-
Record-equalling Red Sox streak halted at 15 wins
-
Tech bounce lifts Asia stocks, oil extends gains on US-Iran fears
-
Messi-less Miami beat Fire 3-2 to spoil Lewandowski's MLS debut
-
Surrounded by militias, Sudanese fear endless cycle of war
-
Mercedes expect Hungary challenge from Hamilton and Ferrari
-
Commonwealth Games 'where champions are made' despite slimmed down model, argues president
-
In Ghana, one man's race to save critically endangered fish
-
Trump family project in Albania has already caused 'irreparable' damage: NGOs
-
Wilson captain, Slipper absent in Kiss's first Wallabies squad
-
Bollywood blast master keeps it real with fire and fury
-
New Mideast fighting puts eurozone rate-setters on alert
-
Tearful fights, edible offerings: A glimpse into the Maradona trial
-
Venezuelans search for animal companions lost in the quakes
-
What's the deal with peptides? The hyped market under US review
-
Argentine Football Association says US did not detain its president
-
Tesla shares fall as Musk touts ambitious -- and costly -- plans
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
S.Gantenbein--VB